Key result
Adjuvant therapies with corticosteroids and anti-TNF-α antibody are necessary for Kawasaki disease patients who are refractory to standard aspirin and intravenous immunoglobulin treatment.
Why the study?
What are the recent updates on the treatment of refractory Kawasaki disease?
What are the recent updates on the treatment of refractory Kawasaki disease?
This review highlights the necessity of adjuvant therapies like corticosteroids and anti-TNF-α antibodies for Kawasaki disease patients refractory to standard IVIG and aspirin.
Supports adjunctive corticosteroids or anti-TNF-α in IVIG-refractory Kawasaki disease; leaves open need for confirmatory RCTs.
Kawasaki disease (KD) was first described by Dr. Tomisaku Kawasaki in his 1975 study, published in Pediatrics. Its pathogenesis is still not clearly understood. Early diagnosis and treatment are very important to preventing concomitant coronary artery complications. Most KD patients respond well to the standard treatment of aspirin and intravenous immunoglobulin; however, some of them are refractory to the standard treatment, and so adjuvant therapies with corticosteroids and anti-tumor necrosis factor-α (TNF-α) antibody are necessary. In this article, the author reviews and summarizes the most recent literature on the treatment of refractory KD.
No takes yet. Share an insight, caveat, or question.
Ji Whan Han (2008) conducted a review in Kawasaki disease. Adjuvant therapies (corticosteroids and anti-TNF-α antibody) vs. Standard treatment (aspirin and intravenous immunoglobulin) was evaluated. Adjuvant therapies with corticosteroids and anti-TNF-α antibody are necessary for Kawasaki disease patients who are refractory to standard aspirin and intravenous immunoglobulin treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: